Publication date: Sep 08, 2025
Patients with B-cell malignancies are at high risk of persisting SARS-CoV-2 infection, which may delay oncologic treatments and increase morbidity. We aimed to assess risk factors for persisting infection in this population. We conducted a multicenter retrospective study across five tertiary hospitals between January 1, 2022, and January 1, 2023. Adult patients with B-cell malignancies and SARS-CoV-2 infection were included. Persisting infection was defined as viral shedding ≥21 days with clinical and/or radiological signs. Risk factors were evaluated through multivariable logistic regression. Among 307 patients, 26. 1% developed persisting infection. The cohort included non-Hodgkin lymphoma (67. 4%), chronic lymphocytic leukemia (19. 2%), and Hodgkin lymphoma (9. 1%). Independent risk factors included anti-CD20 therapy (OR 3. 22; 95% CI 2. 37-4. 39; p
| Concepts | Keywords |
|---|---|
| January | B-cell malignancies |
| Leukemia | Persisting SARS-CoV-2 infection |
| Therapy | |
| Viral |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | SARS-CoV-2 Infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | IDO | cell |
| disease | MESH | Malignancies |
| disease | MESH | morbidity |
| disease | MESH | infection |
| disease | MESH | viral shedding |
| disease | MESH | non-Hodgkin lymphoma |
| disease | MESH | chronic lymphocytic leukemia |
| disease | MESH | Hodgkin lymphoma |